<DOC>
	<DOCNO>NCT00470574</DOCNO>
	<brief_summary>RATIONALE : Vaccines may help body build effective immune response kill tumor cell . Giving vaccine therapy together QS21 may cause strong immune response kill tumor cell . PURPOSE : This clinical trial study side effect well give vaccine therapy together QS21 work treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Vaccine Therapy QS21 Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine QS21 immunoadjuvant patient metastatic breast cancer . - Determine IgG IgM antibody response regimen patient . - Determine proportion breast cancer cell express antigen patient . Secondary - Monitor presence circulate tumor cell prior , , regimen patient . OUTLINE : Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously ( SC ) QS21 immunoadjuvant SC week 1 , 2 , 3 , 7 , 19 absence disease progression unacceptable disease . Blood sample collect periodically evaluate circulate tumor cell reactivity sialyl Lewisª antigen ELISA and/or immunoprecipitation-western blot assay . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV breast cancer meet 1 follow criterion : No evidence disease Stable disease hormonal therapy Stable disease must present ≥ 2 month include &lt; 30 % decrease &lt; 20 % increase sum long diameter target lesion No new target lesion unequivocal progression nontarget lesion Elevation CA 153 ( BR2729 ) CEA value allow Hormone receptor status specify PATIENT CHARACTERISTICS : Female male Menopausal status specify Karnofsky performance status 80100 % Lymphocyte count ≥ 500/mm³ WBC ≥ 3,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 1.5 time ULN Alkaline phosphatase ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergy seafood No NYHA class IIIIV cardiac disease No active cancer except basal cell squamous cell carcinoma skin No active infection require antibiotic treatment No known history immunodeficiency autoimmune disease PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior chemotherapy At least 4 week since prior radiotherapy At least 4 week since prior surgery At least 6 week since prior immunotherapy No prior sialyl Lewisª antigen No concurrent immunosuppressive medication ( i.e. , corticosteroid ) Concurrent hormonal therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>